RT Journal Article
SR Electronic
T1 Emergence of Low-density Inflammatory Neutrophils Correlates with Hypercoagulable State and Disease Severity in COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.22.20106724
DO 10.1101/2020.05.22.20106724
A1 Samantha M. Morrissey
A1 Anne E. Geller
A1 Xiaoling Hu
A1 David Tieri
A1 Elizabeth A. Cooke
A1 Chuanlin Ding
A1 Matthew Woeste
A1 Huang-ge Zhang
A1 Rodrigo Cavallazzi
A1 Sean P. Clifford
A1 James Chen
A1 Lu Cai
A1 Maiying Kong
A1 Corey T. Watson
A1 Jiapeng Huang
A1 Jun Yan
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.22.20106724.abstract
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel viral pathogen that causes a clinical disease called coronavirus disease 2019 (COVID-19). Approximately 20% of infected patients experience a severe manifestation of the disease, causing bilateral pneumonia and acute respiratory distress syndrome. Severe COVID-19 patients also have a pronounced coagulopathy with approximately 30% of patients experiencing thromboembolic complications. However, the etiology driving the coagulopathy remains unknown. Here, we explore whether the prominent neutrophilia seen in severe COVID-19 patients contributes to inflammation-associated coagulation. We found in severe patients the emergence of a CD16IntCD44lowCD11bInt low-density inflammatory band (LDIB) neutrophil population that trends over time with changes in disease status. These cells demonstrated spontaneous neutrophil extracellular trap (NET) formation, phagocytic capacity, enhanced cytokine production, and associated clinically with D-dimer and systemic IL-6 and TNF-α levels, particularly for CD40+ LDIBs. We conclude that the LDIB subset contributes to COVID-19-associated coagulopathy (CAC) and could be used as an adjunct clinical marker to monitor disease status and progression. Identifying patients who are trending towards LDIB crisis and implementing early, appropriate treatment could improve all-cause mortality rates for severe COVID-19 patients.One Sentence Summary In this study, we discover that low-density neutrophils significantly contribute to COVID-19-associated coagulopathy and inflammationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly supported by the Bill and Lindy Street Gift FundAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB# 20.0321. University of LouisvilleAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesYes all raw data are available upon request